<?xml version='1.0' encoding='utf-8'?>
<document id="32250177"><sentence text="Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy." /><sentence text="Introduction: Transgender persons are at increased risk of HIV infection and would benefit from pre-exposure prophylaxis (PrEP) use" /><sentence text=" However, barriers to healthcare and a lack of data regarding PrEP efficacy among transgender persons limits use" /><sentence text=" A related issue is whether a drug-drug interaction (DDI) exists between gender affirming hormone therapy (GAHT) and PrEP" /><sentence text=" Recently, small pharmacokinetic studies were conducted to assess this interaction" /><sentence text="Areas covered: This review will assess the pharmacology of PrEP agents, existing data regarding potential DDIs between GAHT and PrEP, and hypothetical mechanisms for these DDIs" /><sentence text=" A summary will be provided on implications for PrEP use among transgender persons" /><sentence text="Expert opinion: Theoretically, DDIs are not expected between GAHT and PrEP" /><sentence text=" However, among transgender women (TGW) on GAHT, small studies identified a minor DDI between GAHT and tenofovir/emtricitabine (TFV/FTC), with TFV/FTC exposures ~12-27% lower among TGW vs"><entity charOffset="103-112" id="DDI-PubMed.32250177.s9.e0" text="tenofovir" /><entity charOffset="113-126" id="DDI-PubMed.32250177.s9.e1" text="emtricitabine" /><entity charOffset="128-131" id="DDI-PubMed.32250177.s9.e2" text="TFV" /><entity charOffset="132-135" id="DDI-PubMed.32250177.s9.e3" text="FTC" /><entity charOffset="143-145" id="DDI-PubMed.32250177.s9.e4" text="TFV" /><entity charOffset="147-149" id="DDI-PubMed.32250177.s9.e5" text="FTC" /><pair ddi="false" e1="DDI-PubMed.32250177.s9.e0" e2="DDI-PubMed.32250177.s9.e0" /><pair ddi="false" e1="DDI-PubMed.32250177.s9.e0" e2="DDI-PubMed.32250177.s9.e1" /><pair ddi="false" e1="DDI-PubMed.32250177.s9.e0" e2="DDI-PubMed.32250177.s9.e2" /><pair ddi="false" e1="DDI-PubMed.32250177.s9.e0" e2="DDI-PubMed.32250177.s9.e3" /><pair ddi="false" e1="DDI-PubMed.32250177.s9.e0" e2="DDI-PubMed.32250177.s9.e4" /><pair ddi="false" e1="DDI-PubMed.32250177.s9.e0" e2="DDI-PubMed.32250177.s9.e5" /><pair ddi="false" e1="DDI-PubMed.32250177.s9.e1" e2="DDI-PubMed.32250177.s9.e1" /><pair ddi="false" e1="DDI-PubMed.32250177.s9.e1" e2="DDI-PubMed.32250177.s9.e2" /><pair ddi="false" e1="DDI-PubMed.32250177.s9.e1" e2="DDI-PubMed.32250177.s9.e3" /><pair ddi="false" e1="DDI-PubMed.32250177.s9.e1" e2="DDI-PubMed.32250177.s9.e4" /><pair ddi="false" e1="DDI-PubMed.32250177.s9.e1" e2="DDI-PubMed.32250177.s9.e5" /><pair ddi="false" e1="DDI-PubMed.32250177.s9.e2" e2="DDI-PubMed.32250177.s9.e2" /><pair ddi="false" e1="DDI-PubMed.32250177.s9.e2" e2="DDI-PubMed.32250177.s9.e3" /><pair ddi="false" e1="DDI-PubMed.32250177.s9.e2" e2="DDI-PubMed.32250177.s9.e4" /><pair ddi="false" e1="DDI-PubMed.32250177.s9.e2" e2="DDI-PubMed.32250177.s9.e5" /><pair ddi="false" e1="DDI-PubMed.32250177.s9.e3" e2="DDI-PubMed.32250177.s9.e3" /><pair ddi="false" e1="DDI-PubMed.32250177.s9.e3" e2="DDI-PubMed.32250177.s9.e4" /><pair ddi="false" e1="DDI-PubMed.32250177.s9.e3" e2="DDI-PubMed.32250177.s9.e5" /><pair ddi="false" e1="DDI-PubMed.32250177.s9.e4" e2="DDI-PubMed.32250177.s9.e4" /><pair ddi="false" e1="DDI-PubMed.32250177.s9.e4" e2="DDI-PubMed.32250177.s9.e5" /></sentence><sentence text=" cisgender men" /><sentence text=" The mechanism of DDIs is unclear and requires further study" /><sentence text=" For perspective, median TFV/FTC concentrations were still within the range of median concentrations reported across controlled pharmacokinetic studies"><entity charOffset="25-27" id="DDI-PubMed.32250177.s12.e0" text="TFV" /><entity charOffset="29-31" id="DDI-PubMed.32250177.s12.e1" text="FTC" /><pair ddi="false" e1="DDI-PubMed.32250177.s12.e0" e2="DDI-PubMed.32250177.s12.e0" /><pair ddi="false" e1="DDI-PubMed.32250177.s12.e0" e2="DDI-PubMed.32250177.s12.e1" /></sentence><sentence text=" TFV-disphosphate/FTC-triphosphate concentrations were similar between TGW and cisgender men"><entity charOffset="1-17" id="DDI-PubMed.32250177.s13.e0" text="TFV-disphosphate" /><entity charOffset="18-34" id="DDI-PubMed.32250177.s13.e1" text="FTC-triphosphate" /><pair ddi="false" e1="DDI-PubMed.32250177.s13.e0" e2="DDI-PubMed.32250177.s13.e0" /><pair ddi="false" e1="DDI-PubMed.32250177.s13.e0" e2="DDI-PubMed.32250177.s13.e1" /></sentence><sentence text=" In summary, TDF/FTC likely reaches protective concentrations and should continue to be offered as PrEP for transgender persons"><entity charOffset="17-32" id="DDI-PubMed.32250177.s14.e0" text="FTC" /></sentence><sentence text="" /></document>